¼¼°èÀÇ ¹é½Å ½ÃÀå : ±â¼úº°, À¯Çüº°, ÀûÀÀ Áúȯº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ »ç¿ëÀÚº° ¿¹Ãø(-2029³â)
Vaccines Market by Technology (Conjugate, Recombinant, Live Attenuated, Toxoid, Viral Vector, mRNA), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, HPV, Herpes Zoster, MMR, Rotavirus, RSV), Route of Administration - Global Forecast to 2029
»óǰÄÚµå : 1471462
¸®¼­Ä¡»ç : MarketsandMarkets
¹ßÇàÀÏ : 2024³â 04¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 402 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,950 £Ü 6,817,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,650 £Ü 9,158,000
PDF (5-user License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 5¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,150 £Ü 11,224,000
PDF (Corporate License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÀÌ¿ë Àοø¿¡ Á¦ÇÑÀº ¾øÀ¸³ª, ±¹³»¿¡ ÀÖ´Â »ç¾÷À常 ÇØ´çµÇ¸ç, ÇØ¿Ü ÁöÁ¡ µîÀº Æ÷ÇÔµÇÁö ¾Ê½À´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 13,772,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. (100% ÀÚȸ»ç´Â µ¿ÀÏ ±â¾÷À¸·Î °£Áֵ˴ϴÙ.) Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

(COVID-19 ¹é½Å Æ÷ÇÔ) ¹é½Å ½ÃÀå ±Ô¸ð´Â ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)ÀÌ 4.0%°¡ µÉ °ÍÀ¸·Î º¸À̸ç 2024³â 780¾ï ´Þ·¯¿¡¼­ 2029³â¿¡´Â 949¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

¸¶Âù°¡Áö·Î(COVID-19 ¹é½Å Á¦¿Ü) ¹é½Å ½ÃÀå ±Ô¸ð´Â 2024³â 530¾ï ´Þ·¯¿¡¼­ 2029³â 803¾ï ´Þ·¯¿¡ À̸¦ Àü¸ÁÀ̸ç, ¿¹Ãø ±â°£ µ¿¾È º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 8.7%°¡ µÉ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. ¹é½Å ½ÃÀåÀº ¼¼°è Àα¸ Áõ°¡, °¨¿°ÀÇ À¯Çà, ¿¹¹æ °Ç°­ °ü¸®¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡ µî ¸î °¡Áö ÁÖ¿ä ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ¹é½Å °³Ã´ÀÇ ±â¼úÀû Áøº¸´Â ¼¼°è ¿¹¹æÁ¢Á¾ ÇÁ·Î±×·¥ÀÇ È®´ë¿Í ÇÔ²² ½ÃÀå ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

Á¶»ç ¹üÀ§
Á¶»ç ´ë»ó³âµµ 2022³â-2029³â
±âÁسâ 2023³â
¿¹Ãø ±â°£ 2024³â-2029³â
°ËÅä ´ÜÀ§ ±Ý¾×(10¾ï ´Þ·¯)
ºÎ¹®º° ±â¼úº°, À¯Çüº°, ÀûÀÀ Áúȯº°, Åõ¿© °æ·Îº°, ÃÖÁ¾ »ç¿ëÀÚº°
´ë»ó Áö¿ª ºÏ¹Ì, À¯·´, ¾Æ½Ã¾ÆÅÂÆò¾ç, ¶óƾ¾Æ¸Þ¸®Ä«, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

±â¼úº°·Î´Â ¼¼°è ¹é½Å ½ÃÀå(COVID-19 ¹é½Å Á¦¿Ü)Àº ºÒȰȭ,¾Æ´ÜÀ§ ¹é½Å, ¾àµ¶»ý ¹é½Å, Åå¼ÒÀÌµå ¹é½Å, °áÇÕÇü ¹é½Å, ±âŸ ¹é½ÅÀ¸·Î ±¸ºÐµË´Ï´Ù. 2023³â ¹é½Å ½ÃÀåÀº °áÇÕÇü ¹é½Å ½ÃÀåÀÌ µ¶Á¡ÀûÀ̾ú½À´Ï´Ù. °­·ÂÇÑ R&D ÅõÀÚ, Àü·«Àû ÆÄÆ®³Ê½Ê ¹× ¾çÈ£ÇÑ ±ÔÁ¦ ȯ°æÀÌ °áÇÕ ¹é½ÅÀÇ ¿ìÀ§¸¦ ´õ¿í °­È­ÇÏ°í °¨¿°¼º ´ëÃ¥¿¡ ÇʼöÀûÀÎ µµ±¸·Î¼­ÀÇ ÁöÀ§¸¦ È®°íÈ÷ ÇÏ°í ¹é½Å ½ÃÀåÀÇ Áö¼ÓÀûÀÎ ¼ºÀåÀ» °¡¼Ó Çϰí ÀÖ½À´Ï´Ù.

ÀûÀÀ Áúȯº°·Î, ¹é½Å ½ÃÀå(COVID-19 ¹é½Å Á¦¿Ü)Àº È¥ÇÕ ¹é½Å, HPV, ¼ö¸·¿°±Õ¼º Áúȯ, ´ë»óÆ÷Áø, ·ÎŸ¹ÙÀÌ·¯½º, MMR, Æó·Å±¸±Õ¼º Áúȯ, ÀÎÇ÷翣ÀÚ, ¼öµÎ, °£¿°, DTP, ¼Ò¾Æ¸¶ºñ, RSV ¹× ±âŸ Áúº´ ÀûÀÀÁõÀ¸·Î ±¸ºÐµË´Ï´Ù. 2023³â¿¡´Â HPV ºÐ¾ß°¡ ¹é½Å ½ÃÀåÀ» µ¶Á¡Çß½À´Ï´Ù. RSV ºÐ¾ß´Â »õ·Î¿î HPV ¹é½Å Ãâ½Ã¿Í ÀÓ»ó½ÃÇè Áß °­·ÂÇÑ Á¦Ç° µî ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ 2024³â-2028³âÀÇ ¿¹Ãø ±â°£ µ¿¾È ³ôÀº º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.

º» º¸°í¼­¿¡¼­´Â ¼¼°è ¹é½Å ½ÃÀå¿¡ ´ëÇØ Á¶»çÇßÀ¸¸ç, ±â¼úº°, À¯Çüº°, ÀûÀÀÁúȯº°, Åõ¿©°æ·Îº°, ÃÖÁ¾»ç¿ëÀÚº°, Áö¿ªº° µ¿Çâ ¹× ½ÃÀå ÁøÃâ±â¾÷ ÇÁ·ÎÆÄÀÏ µîÀ» Á¤¸®Çß½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­·Ð

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå Áß¿ä ÀλçÀÌÆ®

Á¦5Àå ½ÃÀå °³¿ä

Á¦6Àå ¹é½Å ½ÃÀå : ±â¼úº°

Á¦7Àå ¹é½Å ½ÃÀå : À¯Çüº°

Á¦8Àå ¹é½Å ½ÃÀå : ÀûÀÀ Áúȯº°

Á¦9Àå ¹é½Å ½ÃÀå : Åõ¿© °æ·Îº°

Á¦10Àå ¹é½Å ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

Á¦11Àå ¹é½Å ½ÃÀå : Áö¿ªº°

Á¦12Àå °æÀï ±¸µµ

Á¦13Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦14Àå ºÎ·Ï

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

The vaccines market (including COVID-19 vaccines) is projected to reach USD 94.9 Billion by 2029 from USD 78.0 Billion in 2024, at a CAGR of 4.0% during the forecast period. Similarly the vaccines market (excluding COVID-19 vaccines) is projected to reach USD 80.3 Billion by 2029 from USD 53.0 Billion in 2024, at a CAGR of 8.7% during the forecast period. The vaccines market is driven by several key factors, including increasing global population, rising prevalence of infectious diseases, and growing awareness of preventive healthcare. Technological advancements in vaccine development, coupled with expanding immunization programs worldwide, contribute to market growth.

Scope of the Report
Years Considered for the Study2022-2029
Base Year2023
Forecast Period2024-2029
Units ConsideredValue (USD) Billion
SegmentsBy Technology, By Type, By Disease Indication, By Route of Administration, By End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, Middle East and Africa

"The conjugate vaccines segment (excluding COVID -19 vaccines) held the dominant share in the vaccines market."

Based on technology, the global vaccines market (excluding COVID-19 vaccines) is segmented into inactivated & subunit vaccines, live attenuated vaccines, toxoid vaccines, conjugate vaccines and other vaccines. Conjugate vaccines segment dominated the vaccine market in 2023. Robust research and development investments, strategic partnerships, and favorable regulatory environments have further bolstered the prominence of conjugated vaccines, solidifying their position as indispensable tools in the fight against infectious diseases and driving sustained growth in the vaccines market.

"HPV segment (excluding COVID-19 vaccines) accounted for the largest share of the disease indication segment in 2023."

Based on disease indication, the vaccines market (excluding COVID-19 vaccines) is segmented into, combination vaccines, HPV, meningococcal disease, herpes zoster, rotavirus, MMR, pneumococcal disease, influenza, varicella, hepatitis, DTP, polio, RSV, and other disease indications. In 2023, HPV segment dominated the vaccines market. RSV segment is anticipated to grow at significant CAGR during the forecast period of 2024-2028 owing to various factors such as launch of new HPV vaccine and robust products under clinical trials.

"Asia Pacific region is likely to grow at a faster pace in the vaccines market (excluding COVID -19 vaccines)."

The vaccines market (excluding COVID-19 vaccines) region is segmented into North America, Europe, Asia Pacific, Latin America, Middle East and the Africa. The Asia-Pacific region is poised to experience significant growth in the vaccines market due to several key factors such as increasing healthcare expenditure in countries like China, India, and Southeast Asian nations are driving demand for vaccines to combat infectious diseases. Expanding government initiatives aimed at improving vaccination coverage and healthcare infrastructure further stimulate market growth.

The primary interviews conducted for this report can be categorized as follows:

List of Companies Profiled in the Report:

Research Coverage:

This report provides a detailed picture of the vaccine market. It aims at estimating the size and future growth potential of the market across different segments such as the technology, type, disease indication, route of administration, end-user and region. The report also includes an in-depth competitive analysis of the key market players along with their company profiles recent developments and key market strategies.

Key Benefits of Buying the Report:

The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall vaccines market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

TABLE OF CONTENTS

1 INTRODUCTION

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

5 MARKET OVERVIEW

6 VACCINES MARKET, BY TECHNOLOGY

7 VACCINES MARKET, BY TYPE

8 VACCINES MARKET, BY DISEASE INDICATION

9 VACCINES MARKET, BY ROUTE OF ADMINISTRATION

10 VACCINES MARKET, BY END USER

11 VACCINES MARKET, BY REGION

12 COMPETITIVE LANDSCAPE

13 COMPANY PROFILES

14 APPENDIX

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â